mRNA nanoparticles restore HER2 and p53 to make HER2-low breast tumors respond to trastuzumab
Lipid nanoparticles delivering HER2 and p53 mRNA sensitized HER2-low breast tumors to trastuzumab and drove tumor regression in mouse models.
Resumen
More than 70% of breast cancers have low or undetectable HER2, so they respond poorly to HER2-targeted drugs. Researchers built a lipid nanoparticle that delivers mRNA to restore two genes, HER2 and p53, in tumor cells. According to the abstract, the combination reprograms the cell cycle and causes synergistic tumor cell death, especially in tumors lacking p53. It also made tumors that were previously unresponsive sensitive to trastuzumab, a HER2-targeting antibody. In mouse models using HER2-low patient-derived xenografts and HER2-negative cell-derived xenografts, the approach produced strong tumor regression. The findings are preclinical, and the authors describe the approach as a potential new option for HER2-low cancers. Human safety and efficacy have not been tested, and this summary draws only on the abstract, since the full paper was not available.
Resumen detallado
Breast cancers with low or absent HER2 make up the large majority of cases, and they often fail to respond to HER2-targeted therapies such as trastuzumab. Patients with HER2-low disease have limited targeted options, and loss of the tumor suppressor p53 can add to treatment resistance.
The research team developed a lipid nanoparticle (LNP) carrying mRNA that restores expression of both HER2 and p53 in tumor cells. The idea is to reprogram the tumor cell cycle. Restoring p53 is meant to reinstate a cell-death and growth-control pathway, while restoring HER2 gives trastuzumab a target to act on.
The abstract reports that the combination produced synergistic tumor cell death, particularly in p53-deficient, HER2-low or HER2-negative breast cancer cells. The treatment also sensitized tumors that had previously not responded to trastuzumab. In vivo, the team tested the approach in HER2-low patient-derived xenograft (PDX) models and HER2-negative cell-derived xenograft (CDX) models, and reported robust tumor regression.
If the findings hold up, this would point to a strategy for turning HER2-low tumors into HER2-targetable ones, which could widen the group of patients who benefit from existing antibody therapy. It also illustrates how mRNA delivery can be used to supply tumor suppressors and therapeutic targets together.
Several caveats apply. The work is preclinical and was done in mouse models, so safety, dosing, off-target delivery and immune responses in humans are unknown. Only the abstract was available for this summary, so details on sample sizes, durability of response, toxicity and comparison groups could not be assessed. Two authors have filed a patent and hold equity in Messerna BioTech, which is a potential conflict of interest. Independent replication and clinical testing would be needed.
Hallazgos clave
- An LNP-delivered mRNA restores both HER2 and p53 expression in tumor cells, reprogramming the cell cycle.
- Combined HER2 and p53 restoration caused synergistic tumor cell death, especially in p53-deficient, HER2-low or HER2-negative cells.
- The treatment sensitized previously unresponsive tumors to the HER2-targeted antibody trastuzumab.
- Robust tumor regression was reported in HER2-low patient-derived xenograft and HER2-negative cell-derived xenograft models.
- Over 70% of breast cancers have low or undetectable HER2, so the approach could address a large unmet need.
Metodología
The study developed a lipid nanoparticle formulation delivering HER2 and p53 mRNA and tested it in breast cancer cells for cell death and trastuzumab sensitization. In vivo efficacy was evaluated in HER2-low patient-derived xenograft and HER2-negative cell-derived xenograft mouse models. Only the abstract was reviewed, so detailed methods are not available.
Limitaciones del estudio
Results come from cell and mouse xenograft models, which may not predict human responses, and safety, biodistribution and immunogenicity data were not described in the abstract. Full methods, sample sizes and durability of effect could not be evaluated. Authors disclose a patent application and equity in Messerna BioTech.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte: